Literature DB >> 19024326

[Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].

Feng Chen1, Wei-min Li, Dong-mei Wang, Shu-sheng Gao, Yong Bao, Wen-bin Chen, Dan Liu.   

Abstract

OBJECTIVE: To investigate the clinical significance of a combination of several serum tumor markers in the diagnosis of lung cancer.
METHODS: Serum CEA, CA125, CA199, CYFRA21-1 and NSE were measured with RIA, chromatometrychemoluminescence, ELISA and biochemoluminescence methods respectively in 340 patients with lung cancers at different TNM stages, 120 patients with benign lung diseases, and 45 healthy people. The sensitivities, specificities and accuracies of different combination of those markers for the diagnosis of lung cancers were compared.
RESULTS: CYFRA21-1 had the highest sensitivity and accuracy (60.0% and 70.3%) and CA199 had the highest specificity (99.4%) for detecting lung cancers. CYFRA21-1 had the highest sensitivity (79.6%) for detecting squamous carcinoma. CEA had the highest sensitivity of (75.7%) for detecting adenocarcinoma. NSE had the highest sensitivity (76.2%) for detecting small cell lung cancers (SCLC). The combination of several serum tumor markers had higher sensitivities than the single marker for the diagnosis of lung cancers. With two markers, the combination of CYFRA21-1 and NSE had the highest sensitivity and accuracy (82.9% and 83.4%), while the combination of CA125 and CA199 had the highest specificity (94.5%). With three markers, the combination of CEA, NSE and CYFRA21-1 had the highest sensitivity and accuracy (89.1% and 85.1%), while the combination of CEA, CA125 and CA199 had the highest specificity (86.7%). The combination of CEA, CA125, CA199, CYFRA21-1 and NSE produced the best value, with a sensitivity of 93.8%, a specificity of 71.5%, and an accuracy of 86.5%.
CONCLUSION: Serum CEA, CA125, CA199, CYFRA21-1 and NSE are helpful markers for the diagnosis of lung cancer. The combination of the markers can improve the sensitivity and accuracy of the diagnosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19024326

Source DB:  PubMed          Journal:  Sichuan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-173X


  3 in total

1.  A multi-analyte serum test for the detection of non-small cell lung cancer.

Authors:  E C Farlow; M S Vercillo; J S Coon; S Basu; A W Kim; L P Faber; W H Warren; P Bonomi; M J Liptay; J A Borgia
Journal:  Br J Cancer       Date:  2010-09-21       Impact factor: 7.640

2.  Gene methylation as a powerful biomarker for detection and screening of non-small cell lung cancer in blood.

Authors:  Bao-Hua Wang; Yan-Yu Li; Jin-Zhu Han; Lian-Ya Zhou; Ying-Qian Lv; He-Lin Zhang; Li Zhao
Journal:  Oncotarget       Date:  2017-05-09

3.  Dynamic monitoring serum tumor markers to predict molecular features of EGFR-mutated lung cancer during targeted therapy.

Authors:  Zhuxing Chen; Liping Liu; Feng Zhu; Xiuyu Cai; Yi Zhao; Peng Liang; Limin Ou; Ran Zhong; Ziwen Yu; Caichen Li; Jianfu Li; Shan Xiong; Yi Feng; Bo Cheng; Hengrui Liang; Zhanhong Xie; Wenhua Liang; Jianxing He
Journal:  Cancer Med       Date:  2022-05-11       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.